​

CRISPR Therapeutics (CRSP) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CRSP Stock Forecast

CRISPR Therapeutics (CRSP) stock forecast, based on 38 Wall Street analysts, predicts a 12-month average price target of $71.67, with a high of $82.00 and a low of $56.00. This represents a 42.68% increase from the last price of $50.23.

$35 $45 $55 $65 $75 $85 High: $82 Avg: $71.67 Low: $56 Last Closed Price: $50.23

CRSP Stock Rating

CRISPR Therapeutics stock's rating consensus is Buy, based on 38 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 22 Buy (57.89%), 14 Hold (36.84%), 2 Sell (5.26%), and 0 Strong Sell (0.00%).

Buy
Total 38 0 2 14 22 Strong Sell Sell Hold Buy Strong Buy

CRSP Price Target Upside V Benchmarks

TypeNameUpside
StockCRISPR Therapeutics42.68%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts3411
Avg Price Target$65.33$68.00$66.91
Last Closing Price$50.23$50.23$50.23
Upside/Downside30.06%35.38%33.21%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2641191-25
May, 2641291-26
Apr, 2651291-27
Mar, 2651291-27
Feb, 2651291-27
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 12, 2026UBS$80.00$50.2359.27%59.27%
Jun 11, 2026Maxwell SkorMorgan Stanley$60.00$49.4421.36%19.45%
May 13, 2026Bernstein$56.00$52.836.00%11.49%
May 11, 2026Evercore ISI$76.00$55.5636.79%51.30%
Feb 17, 2026Morgan Stanley$33.00$52.25-36.84%-34.30%
Feb 14, 2026Geulah LivshitsChardan Capital$76.00$53.0743.21%51.30%
Feb 13, 2026Needham$82.00$53.8952.16%63.25%
Feb 13, 2026Evercore ISI$74.00$53.8137.52%47.32%
Nov 26, 2025Chardan Capital$74.00$52.7940.18%47.32%
Nov 11, 2025Luca IssiRBC Capital$50.00$54.58-8.39%-0.46%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 27, 2026CitigroupMarket OutperformMarket Outperformhold
May 13, 2026BernsteinMarket PerformMarket Performhold
May 11, 2026Evercore ISIOutperformOutperformhold
May 06, 2026CitigroupBuyBuyhold
Feb 17, 2026Morgan StanleyUnderweightUnderweighthold
Feb 16, 2026CitigroupBuyBuyhold
Feb 13, 2026NeedhamBuyBuyhold
Feb 13, 2026Evercore ISIOutperformOutperformhold
Feb 13, 2026Cowen & Co.HoldHoldhold
Jan 30, 2026CitigroupMarket OutperformMarket Outperformhold

Financial Forecast

EPS Forecast

$-40 $-23 $-6 $11 $28 $45 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.97$-8.36$-1.94$-4.34$-6.47---
Avg Forecast$4.88$-9.09$-2.92$-5.17$-5.07$-3.12$-1.00$1.71
High Forecast$44.49$2.49$-1.60$-4.73$-3.01$8.56$9.76$7.17
Low Forecast$-0.68$-36.12$-4.16$-6.53$-6.60$-7.69$-5.76$-0.47
Surprise %1.84%-8.03%-33.56%-16.05%27.61%---

Revenue Forecast

$0 $1B $3B $4B $6B $7B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$913.08M$436.00K$370.00M$35.00M$3.51M---
Avg Forecast$903.86M$6.14M$293.21M$11.13M$118.69M$506.62M$1.02B$1.69B
High Forecast$6.54B$20.20M$377.05M$36.07M$410.38M$516.62M$1.04B$5.85B
Low Forecast$112.01M$122.50K$173.24M$1.21M$2.49M$496.61M$1.01B$35.48M
Surprise %1.02%-92.90%26.19%214.34%-97.04%---

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$377.66M$-650.17M$-153.61M$-366.25M$-581.60M---
Avg Forecast$338.20M$-603.01M$-153.61M$-445.92M$-448.97M$-262.09M$-119.23M$135.47M
High Forecast$554.59M$-482.41M$-122.89M$-374.41M$-238.06M$678.45M$773.32M$568.30M
Low Forecast$121.81M$-723.61M$-184.33M$-517.43M$-522.52M$-609.51M$-456.49M$-36.95M
Surprise %11.67%7.82%--17.87%29.54%---

CRSP Forecast FAQ

Is CRISPR Therapeutics stock a buy?

CRISPR Therapeutics stock has a consensus rating of Buy, based on 38 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 22 Buy, 14 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that CRISPR Therapeutics is a favorable investment for most analysts.

What is CRISPR Therapeutics's price target?

CRISPR Therapeutics's price target, set by 38 Wall Street analysts, averages $71.67 over the next 12 months. The price target range spans from $56 at the low end to $82 at the high end, suggesting a potential 42.68% change from the previous closing price of $50.23.

How does CRISPR Therapeutics stock forecast compare to its benchmarks?

CRISPR Therapeutics's stock forecast shows a 42.68% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for CRISPR Therapeutics over the past three months?

  • June 2026: 16.00% Strong Buy, 44.00% Buy, 36.00% Hold, 4.00% Sell, 0% Strong Sell.
  • May 2026: 15.38% Strong Buy, 46.15% Buy, 34.62% Hold, 3.85% Sell, 0% Strong Sell.
  • April 2026: 18.52% Strong Buy, 44.44% Buy, 33.33% Hold, 3.70% Sell, 0% Strong Sell.

What is CRISPR Therapeutics’s EPS forecast?

CRISPR Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-3.12, marking a -51.78% decrease from the reported $-6.47 in 2025. Estimates for the following years are $-1 in 2027, and $1.71 in 2028.

What is CRISPR Therapeutics’s revenue forecast?

CRISPR Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $506.62M, reflecting a 14333.50% increase from the reported $3.51M in 2025. The forecast for 2027 is $1.02B, and $1.69B for 2028.

What is CRISPR Therapeutics’s net income forecast?

CRISPR Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-262M, representing a -54.94% decrease from the reported $-582M in 2025. Projections indicate $-119M in 2027, and $135.47M in 2028.